Skip to content
AnalystLens

Charles River Laboratories International Annual Report, Year Ended Dec 26, 2009

Filing Date
Filed February 19, 2010
Period End
December 26, 2009
Security
CRL
One revenue dollarkept$0.10
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 10-K filed February 19, 2010. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. reported net sales of $1.20 billiona for fiscal 2009 (ended December 26, 2009), down $140.9 million, or 10.5%, from $1.34 billion in 2008.

The decline was driven mainly by slower demand for Preclinical Services (PCS), where segment sales fell 20.6% to $542.6 millionb amid study slippage, delayed customer decisions, pricing pressure and unfavorable foreign currency. Research Models and Services (RMS) sales were flat at $659.9 million. Operating income rebounded to $166.9 million from a loss of $449.9 million in 2008, which included a $700 million goodwill impairment in the PCS segment.

Net income attributable to common shareowners was $114.4 millionc, or $1.74 per diluted share, versus a loss of $524.5 million in 2008. Management described 2009 as a challenging year for preclinical services and said it expects PCS demand to begin ramping up slowly in the second quarter of 2010. To lower costs and align capacity, the company cut about 1,000 jobs, closed its Arkansas facility, and announced in January 2010 the suspension of its Shrewsbury, Massachusetts PCS facility by mid-2010, with expected charges of approximately $6 million to $7 million and cost savings of about $40 million in 2009 and $70 million in 2010.

Cash flow from operations was $217.4 milliond, capital expenditures were $80.0 million, and total debt was $492.8 million at year-end. The company did not repurchase shares in the fourth quarter, with about $144.8 million remaining under its repurchase authorization. The filing identifies key risks including reduced pharmaceutical and biotechnology R&D budgets, customer termination rights on short notice, fixed-price contract exposure, international operations (roughly half of net sales), proposed U.S. and Canadian tax law changes, and goodwill impairment risk given $668.5 million of goodwill and other intangibles.

Key Highlights

  1. Net sales of $1.20 billion in 2009, down 10.5% from $1.34 billion in 2008; PCS sales fell 20.6% while RMS sales were flat at $659.9 million.
  2. Operating income of $166.9 million in 2009 versus an operating loss of $449.9 million in 2008, which included a $700 million PCS goodwill impairment.
  3. Net income attributable to common shareowners of $114.4 million, or $1.74 diluted EPS, compared with a loss of $524.5 million in 2008.
  4. Gross margin fell to 35.7% of net sales from 38.0%; PCS gross margin declined from 33.1% to 27.8%.
  5. Restructuring: about 1,000 headcount reduction, closure of the Arkansas facility, and planned suspension of the Shrewsbury, Massachusetts PCS facility by mid-2010, with projected 2010 cost savings of about $70 million.
  6. Cash flow from operations of $217.4 million and capital expenditures of $80.0 million; 2010 capex planned at $60 million to $70 million.
  7. Total debt of $492.8 million at year-end, with a $350 million 2.25% convertible note due 2013 and no dividends paid or planned.

Follow one dollar

Of each $1.00 of revenue in FY2009, Charles River Laboratories International kept $0.10.

  1. Revenue$1.17B100.0%
  2. Cost of revenue−$255.7M21.8%
  3. Gross profit$916.0M78.2%
  4. Operating costs−$746.3M63.7%
  5. Operating income$169.6M14.5%
  6. Interest, other & tax−$55.2M4.7%
  7. Net income$114.4M9.8%
Computed from 10-KFY2009filed February 19, 2010Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2009 revenue went

$1.17B
  • Other operating costs: $518.7M, 44% of revenue
  • Cost of revenue: $255.7M, 22% of revenue
  • SG&A: $227.7M, 19% of revenue
  • Net income: $114.4M, 9.8% of revenue
  • Interest, other & tax: $55.2M, 4.7% of revenue

Kept 9.8% as net incomeNet income $114.4M · 9.8%

Full revenue history →

Financial Statements

FY2009 against FY2008

Line itemFY2009FY2008Change
Revenue$1.17B$1.30B−9.5%
Cost of Revenue$255.68M$252.94M+1.1%
Gross Profit$915.96M$1.04B−12.1%
SG&A Expenses$227.66M$223.94M+1.7%
Operating Income$169.61M-$451.84M+137.5%
Interest Expense$21.68M$22.34M−2.9%
Net Income$114.44M-$524.50M+121.8%
EPS (Basic)$1.75$-7.80+122.4%
EPS (Diluted)$1.74$-7.80+122.3%
Shares Outstanding (Basic)65.37M——
Shares Outstanding (Diluted)65.64M——

Frequently Asked Questions

  1. Why did revenue decline in 2009?

    Management attributed the 10.5% decline in net sales mainly to slower demand for Preclinical Services, including study slippage and delays in customer decisions, biotechnology funding constraints, tight customer cost controls leading to pricing pressure, and a focus on late-stage human testing. Unfavorable foreign currency translation reduced sales by 2.3%.

  2. Why did the company post a large loss in 2008 but profit in 2009?

    The 2008 results included a $700 million goodwill impairment charge related to the PCS segment, which produced an operating loss of $449.9 million. No goodwill impairment was recorded in 2009, and operating income was $166.9 million.

  3. What actions is the company taking to address weaker demand?

    The company reduced headcount by about 1,000, mainly in PCS, closed its Arkansas facility and two small RMS sites, realigned its PCS organization and sales and marketing team, and announced the suspension of its Shrewsbury, Massachusetts facility by mid-2010. It expects these actions to reduce costs by about $40 million in 2009 and $70 million in 2010, and it expects severance and related charges of approximately $7 million, mainly in the first quarter of 2010.

  4. What are the main risks highlighted for investors?

    Key risks include a possible decrease in outsourcing or R&D budgets at pharmaceutical and biotechnology companies, customer contracts that can be terminated on little or no notice, fixed-price contracts that may lead to losses, international operations accounting for about one-half of net sales, possible U.S. and Canadian tax law changes, and potential goodwill impairment given $668.5 million of goodwill and other intangibles.

  5. What is the company's capital structure and shareholder return policy?

    Total debt was $492.8 million at December 26, 2009, including the $350 million 2.25% convertible senior notes due 2013 and term loans and revolver borrowings under its credit agreements. The company has not paid cash dividends in the past two years and does not intend to in the foreseeable future. About $144.8 million remained authorized for share repurchases, and no shares were repurchased in the fourth quarter of 2009.